First Trust Direct Indexing’s Pacira BioSciences PCRX Stock Holding History

First Trust Direct Indexing’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,338	Closed	-$234K	–	599
2021 Q1	$234K	Sell	3,338 -756	-18%	-$54K	0.06%	351
2020 Q4	$245K	Buy	+4,094	New	+$240K	0.07%	325

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

First Trust Direct Indexing's PCRX Position: Q2 2021 in Review

First Trust Direct Indexing sold out of Pacira BioSciences (PCRX) in Q2 2021, closing a stake of 3,338 shares — an estimated $234K sold.

First Trust Direct Indexing first reported a position in PCRX in Q4 2020 and held it in 2 quarters. The position peaked at $245K in Q4 2020. 262 funds tracked by Wall St. Rank hold PCRX as of Q2 2021.

First Trust Direct Indexing reported no remaining Pacira BioSciences position as of Q2 2021 after selling out during the quarter.
First Trust Direct Indexing sold 3,338 Pacira BioSciences shares in Q2 2021, an estimated $234K.
First Trust Direct Indexing first reported a position in Pacira BioSciences in Q4 2020 and held it in 2 quarters.
First Trust Direct Indexing's Pacira BioSciences position peaked at $245K in Q4 2020.
262 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2021.

Based on First Trust Direct Indexing's 13F filing for Q2 2021, filed 13 Jul 2021.